Advertisement

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology: Erratum

        A recently published article [Lindeman NI, Cagle PT, Beasley MB, et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859] contains an error in Table 4, EGFR Mutation Prevalence in Different Lung Adenocarcinoma Patient Populations, and in Supplemental Table 5, EGFR Mutation Prevalence in Different Lung Adenocarcinoma Patient Populations. These analyses failed to distinguish between European Spanish and Latin American (Hispanic) populations. Re-analysis of the 4 studies originally cited as providing data for Latin American (Hispanic) populations led to the re-categorization of 369 patients, with only 3 remaining Latin American (Hispanic) patients, which was too limited for meaningful analysis of this population. The re-categorization of the remaining 369 patients did not make a significant change in the data for the other patient populations as originally presented in Table 4 and in Supplemental Table 5.

        Reference

          • Lindeman NI
          • Cagle PT
          • Beasley MB
          • Chitale DA
          • Dacic S
          • Giaccone G
          • Jenkins RB
          • Kwiatkowski DJ
          • Saldivar JS
          • Squire J
          • Thunnissen E
          • Ladanyi M
          Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
          J Thorac Oncol. 2013; 8: 823-859